159 related articles for article (PubMed ID: 11895216)
21. Growth hormone responses to growth hormone-releasing hormone and clonidine before and after erythropoietin therapy in CAPD patients.
Díez J; Iglesias P; Sastre J; Méndez J; Selgas R; Gómez-Pan A
Nephron; 1996; 74(3):548-54. PubMed ID: 8938679
[TBL] [Abstract][Full Text] [Related]
22. The influence of gender on the short and long-term effects of growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults: a 5-year study.
Drake WM; Rodríguez-Arnao J; Weaver JU; James IT; Coyte D; Spector TD; Besser GM; Monson JP
Clin Endocrinol (Oxf); 2001 Apr; 54(4):525-32. PubMed ID: 11318789
[TBL] [Abstract][Full Text] [Related]
23. Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency.
Janssen YJ; Hamdy NA; Frölich M; Roelfsema F
J Clin Endocrinol Metab; 1998 Jun; 83(6):2143-8. PubMed ID: 9626153
[TBL] [Abstract][Full Text] [Related]
24. Gender differences in growth hormone response to exercise before and after rhGH administration and the effect of rhGH on the hormone profile of fit normal adults.
Giannoulis MG; Boroujerdi MA; Powrie J; Dall R; Napoli R; Ehrnborg C; Pentecost C; Cittadini A; Jørgensen JO; Sonksen PH;
Clin Endocrinol (Oxf); 2005 Mar; 62(3):315-22. PubMed ID: 15730413
[TBL] [Abstract][Full Text] [Related]
25. Short-term therapy with recombinant growth hormone in polytransfused thalassaemia major patients with growth deficiency.
Cavallo L; Gurrado R; Zecchino C; Manolo F; De Sanctis V; Cisternino M; Caruso-Nicoletti M; Galati M
J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():845-9. PubMed ID: 10091155
[TBL] [Abstract][Full Text] [Related]
26. Monitoring serum insulin-like growth factor-I (IGF-I), IGF binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and leptin during growth hormone treatment for disordered growth.
Tillmann V; Patel L; Gill MS; Whatmore AJ; Price DA; Kibirige MS; Wales JK; Clayton PE
Clin Endocrinol (Oxf); 2000 Sep; 53(3):329-36. PubMed ID: 10971450
[TBL] [Abstract][Full Text] [Related]
27. The growth hormone cascade: progress and long-term results of growth hormone treatment in growth hormone deficiency.
Grumbach MM; Bin-Abbas BS; Kaplan SL
Horm Res; 1998; 49 Suppl 2():41-57. PubMed ID: 9730672
[TBL] [Abstract][Full Text] [Related]
28. Growth hormone (GH) replacement therapy reduces serum sialic acid concentrations in adults with GH-deficiency: a double-blind placebo-controlled study.
Christ ER; Cummings MH; Lumb PJ; Crook MA; Sönksen PH; Russell-Jones DL
Clin Endocrinol (Oxf); 1999 Aug; 51(2):173-9. PubMed ID: 10468987
[TBL] [Abstract][Full Text] [Related]
29. Short-term recombinant human growth hormone therapy does not modify growth hormone, thyrotropin and prolactin responses to thyrotropin-releasing hormone in adult dialysis patients.
Iglesias P; Selgas R; Méndez J; Fernández-Reyes MJ; Bajo MA; Aguilera A; Díez JJ
Nephrol Dial Transplant; 2000 Jun; 15(6):856-61. PubMed ID: 10831641
[TBL] [Abstract][Full Text] [Related]
30. Effects of short-term recombinant human growth hormone therapy on plasma leptin concentrations in dialysis patients.
Iglesias P; Díez JJ; Fernández-Reyes MJ; Bajo MA; Aguilera A; Méndez J; Codoceo R; Selgas R
Nephrol Dial Transplant; 2002 Feb; 17(2):260-4. PubMed ID: 11812876
[TBL] [Abstract][Full Text] [Related]
31. Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients.
Laursen T; Jørgensen JO; Jakobsen G; Hansen BL; Christiansen JS
J Clin Endocrinol Metab; 1995 Aug; 80(8):2410-8. PubMed ID: 7543114
[TBL] [Abstract][Full Text] [Related]
32. Do growth hormone (GH) serial sampling, insulin-like growth factor-I (IGF-I) or auxological measurements have an advantage over GH stimulation testing in predicting the linear growth response to GH therapy?
Rogol AD; Blethen SL; Sy JP; Veldhuis JD
Clin Endocrinol (Oxf); 2003 Feb; 58(2):229-37. PubMed ID: 12580940
[TBL] [Abstract][Full Text] [Related]
33. Effect of haemoglobin and endogenous erythropoietin on hypothalamic-pituitary thyroidal and gonadal secretion: an analysis of anaemic (high EPO) and polycythaemic (low EPO) patients.
Ramirez G; Bittle PA; Rabb HA; Ballester O; Bercu BB
Clin Endocrinol (Oxf); 1995 Aug; 43(2):167-74. PubMed ID: 7554311
[TBL] [Abstract][Full Text] [Related]
34. Differential effects of growth hormone therapy in malnourished hemodialysis patients.
Kotzmann H; Yilmaz N; Lercher P; Riedl M; Schmidt A; Schuster E; Kreuzer S; Geyer G; Frisch H; Hörl WH; Mayer G; Luger A
Kidney Int; 2001 Oct; 60(4):1578-85. PubMed ID: 11576376
[TBL] [Abstract][Full Text] [Related]
35. The effect of recombinant human growth hormone on regulation of growth hormone secretion and blood glucose in insulin-dependent diabetes.
Wurzburger MI; Prelevic GM; Sönksen PH; Balint-Peric LA; Wheeler M
J Clin Endocrinol Metab; 1993 Jul; 77(1):267-72. PubMed ID: 8325951
[TBL] [Abstract][Full Text] [Related]
36. The absorption profile and availability of a physiological subcutaneously administered dose of recombinant human growth hormone (GH) in adults with GH deficiency.
Janssen YJ; Frölich M; Roelfsema F
Br J Clin Pharmacol; 1999 Mar; 47(3):273-8. PubMed ID: 10215751
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
[TBL] [Abstract][Full Text] [Related]
38. Administration of recombinant human growth hormone normalizes GH-IGF1 axis and improves malnutrition-related disorders in patients with anorexia nervosa.
Hashizume K; Suzuki S; Komatsu A; Hiramatsu K; Mori J; Yamazaki M; Takeda T; Kakizawa T; Miyamoto T; Koizumi Y; Ichikawa K
Endocr J; 2007 Apr; 54(2):319-27. PubMed ID: 17339748
[TBL] [Abstract][Full Text] [Related]
39. Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults.
Laursen T; Gravholt CH; Heickendorff L; Drustrup J; Kappelgaard AM; Jørgensen JO; Christiansen JS
J Clin Endocrinol Metab; 2001 Mar; 86(3):1222-8. PubMed ID: 11238512
[TBL] [Abstract][Full Text] [Related]
40. Pre-treatment IGF-I level is the major determinant of GH dosage in adult GH deficiency.
Murray RD; Howell SJ; Lissett CA; Shalet SM
Clin Endocrinol (Oxf); 2000 May; 52(5):537-42. PubMed ID: 10792331
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
